Paloset Tablet

About Paloset .5 mg Tablet

Paloset is a .5 mg tablet from Square Pharmaceuticals PLC. It contains the generic palonosetron and belongs to the anti-emetic group of medicines, which are used to help control nausea and vomiting in certain treatment situations.

There are 16 brands of Palonosetron listed in Bangladesh.

What is Paloset .5 mg Tablet?

Paloset is a tablet made by Square Pharmaceuticals PLC. Its active ingredient is palonosetron, and it is grouped with anti-emetic medicines, which are used to help manage nausea and vomiting. It is commonly given in connection with treatments such as chemotherapy or radiotherapy, and may also be used for nausea and vomiting after surgery. It works by blocking a body signal involved in the vomiting reflex. The doctor decides whether it is suitable and how it should be taken.

Uses of Paloset

Paloset is used to help control nausea and vomiting. This includes nausea and vomiting caused by certain chemotherapy treatments, both on the day of treatment and on later days, as well as nausea and vomiting linked to radiotherapy. It may also be used for nausea and vomiting that is not well controlled, and for nausea and vomiting after surgery. Your doctor will decide if it is right for your situation.

How to use Paloset

Take Paloset exactly as your doctor tells you. The doctor decides the dose, when to take it and how long the course should last. Swallow the tablet with water, unless your doctor gives other instructions. Do not change the dose or stop on your own. If you are unsure how or when to take it, ask your doctor or pharmacist. Store it in a cool, dry place away from light.

Side effects of Paloset

The most common side effects are headache and constipation. Not everyone who takes it will have these effects. If you notice any side effect that worries you, or if it does not settle, tell your doctor or pharmacist. They can advise you on what to do. Do not start or stop any other medicine without checking with your doctor or pharmacist first.

Safety and precautions

Do not take Paloset if you have had an allergic reaction to palonosetron or to any of the ingredients in the tablet. Tell your doctor about any allergies and about other medicines you take. If you are pregnant, think you may be pregnant, or are breastfeeding, ask your doctor before taking it, because it is not known whether it passes into breast milk. People with other health conditions should check with the doctor first. The doctor will decide if it is suitable for you.

Frequently asked questions

What does the generic name palonosetron mean?

Palonosetron is the generic name of the active ingredient in Paloset. It is the standard name used for this substance, while Paloset is the brand name given by the company. Generic and brand names describe the same active ingredient.

What is Paloset used for, and what kind of medicine is it?

Paloset is an anti-emetic medicine, which means it is used to help control nausea and vomiting. It is used in situations such as nausea and vomiting caused by certain chemotherapy or radiotherapy, or after surgery. Your doctor will decide if it is suitable for you.

Who should avoid Paloset or ask the doctor first?

Do not take it if you are allergic to palonosetron or any ingredient in the tablet. If you are pregnant, may be pregnant or are breastfeeding, ask your doctor first. People with other health conditions or who take other medicines should check with the doctor before use.

How should I store Paloset?

Keep Paloset in a cool, dry place and protect it from light. Keep it out of reach of children. If you are unsure about storage, ask your pharmacist for advice.

Indications

Palonosetron indicated in-
  • Acute and delayed nausea and vomiting
  • Uncontrolled nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
  • Delayed CINV resulting in on days later with certain types of chemotherapy
  • ... Read more
Palonosetron indicated in-
  • Acute and delayed nausea and vomiting
  • Uncontrolled nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
  • Delayed CINV resulting in on days later with certain types of chemotherapy
  • Radiotherapy-induced nausea and vomiting (RINV)
  • Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).

Pharmacology

Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors that are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema, to initiate the vomiting reflex. Postoperative nausea and vomiting is influenced by multiple patient, surgical and anesthesia related factorcs and is triggered by release of 5-HT3 in a cascade of neuronal event involving both the central nervous system and the gastrointestinal tract. The 5-HT3 receptor has been demonstrated to selectively participate in the emetic response. Palonosetron works by blocking the actions of Serotonin, associated with nausea and vomiting, at 5-HTs receptor. It is likely that Palonosetron works in the small intestine but it may also work in the brain.

Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.

Dosage & Administration

Usual dosage: Adult tablet dosage: 0.5 mg daily. Adult IV dosage: A single IV dose of 0.075 mg should be administered over 10 seconds.

Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.

Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.

Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.

Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.

Interaction

In controlled clinical trials, Palonosetron injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents. Palonosetron did not inhibit the antitumor activity of cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C in murine tumor models. Concomitant administration of Palonosetron and metoclopramide has no significant pharmacokinetic interactions. In vitro studies indicated that palonosetron is not inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 & CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6 or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with Palonosetron appears to be low.

Contraindications

Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components.

Side Effects

The most common adverse reactions are headaches and constipation.

Pregnancy & Lactation

Pregnancy category 'B'. It is not known whether Palonosetron is excreted in breast milk.

Overdose Effects

There is no known antidote to Palonosetron. Overdose should be managed with supportive care.

Storage Conditions

Store in a cool & dry place, protected from light.

Alternative brands of Palonosetron

Other brands with the same generic name, cheapest first.

See all 16 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.